TY - JOUR
T1 - Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
AU - Bailey, Howard H.
AU - Ripple, Greg
AU - Tutsch, Kendra D.
AU - Arzoomanian, Rhoda Z.
AU - Alberti, Dona
AU - Feierabend, Chris
AU - Mahvi, David
AU - Schink, Julian
AU - Pomplun, Marcia
AU - Mulcahy, R. Timothy
AU - Wilding, George
PY - 1997/12/3
Y1 - 1997/12/3
N2 - Background: Increased intracellular glutathione has long been associated with tumor cell resistance to various cytotoxic agents. An inhibitor of glutathione biosynthesis, L-S,R-buthionine sulfoximine (BSO), has been shown to enhance the cytotoxicity of chemotherapeutic agents in vitro and in vivo. We performed a phase I study of BSO administered with the anticancer drug melphalan to determine the combination's safety/tolerability and to determine clinically whether BSO produced the desired biochemical end point of glutathione depletion (<10% of pretreatment value). Methods: Twenty-one patients with advanced cancers received an initial 30-minute infusion of BSO totaling 3.0 g/m2 and immediately received a continuous infusion of BSO on one of the following schedules: 1) 0.75 g/m2 per hour for 24 hours (four patients); 2) the same dose rate for 48 hours (four patients); 3) the same dose rate for 72 hours (10 patients); or 4) 1.5 g/m2 per hour for 48 hours (three patients). During week 1, the patients received BSO alone; during weeks 2 or 3, they received BSO plus melphalan (15 mg/m2); thereafter, the patients received BSO plus melphalan every 4 weeks. Glutathione concentrations in peripheral blood lymphocytes were determined for all patients; in 10 patients on three of the administration schedules, these measurements were made in multiple sections from tumor biopsy specimens taken before, during, and after continuous-infusion BSO. Results: Continuous- infusion BSO alone produced minimal toxic effects, although BSO plus melphalan produced occasional severe myelosuppression (grade 4) and frequent low-grade nausea/vomiting (grade 1-2). This treatment also produced consistent, profound glutathione depletion (<10% of pretreatment value). The degree of glutathione depletion in peripheral lymphocytes was considerably less than that observed in tumor sections. Conclusions: Continuous-infusion BSO is relatively nontoxic and results in depletion of tumor glutathione.
AB - Background: Increased intracellular glutathione has long been associated with tumor cell resistance to various cytotoxic agents. An inhibitor of glutathione biosynthesis, L-S,R-buthionine sulfoximine (BSO), has been shown to enhance the cytotoxicity of chemotherapeutic agents in vitro and in vivo. We performed a phase I study of BSO administered with the anticancer drug melphalan to determine the combination's safety/tolerability and to determine clinically whether BSO produced the desired biochemical end point of glutathione depletion (<10% of pretreatment value). Methods: Twenty-one patients with advanced cancers received an initial 30-minute infusion of BSO totaling 3.0 g/m2 and immediately received a continuous infusion of BSO on one of the following schedules: 1) 0.75 g/m2 per hour for 24 hours (four patients); 2) the same dose rate for 48 hours (four patients); 3) the same dose rate for 72 hours (10 patients); or 4) 1.5 g/m2 per hour for 48 hours (three patients). During week 1, the patients received BSO alone; during weeks 2 or 3, they received BSO plus melphalan (15 mg/m2); thereafter, the patients received BSO plus melphalan every 4 weeks. Glutathione concentrations in peripheral blood lymphocytes were determined for all patients; in 10 patients on three of the administration schedules, these measurements were made in multiple sections from tumor biopsy specimens taken before, during, and after continuous-infusion BSO. Results: Continuous- infusion BSO alone produced minimal toxic effects, although BSO plus melphalan produced occasional severe myelosuppression (grade 4) and frequent low-grade nausea/vomiting (grade 1-2). This treatment also produced consistent, profound glutathione depletion (<10% of pretreatment value). The degree of glutathione depletion in peripheral lymphocytes was considerably less than that observed in tumor sections. Conclusions: Continuous-infusion BSO is relatively nontoxic and results in depletion of tumor glutathione.
UR - http://www.scopus.com/inward/record.url?scp=0030658870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030658870&partnerID=8YFLogxK
U2 - 10.1093/jnci/89.23.1789
DO - 10.1093/jnci/89.23.1789
M3 - Article
C2 - 9392620
AN - SCOPUS:0030658870
SN - 0027-8874
VL - 89
SP - 1789
EP - 1796
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 23
ER -
